The prevalence of insomnia in the elderly is significant. If left untreated or inappropriately treated, insomnia may contribute to increased health care resource use. Therefore, better identification and management of insomnia is required for this patient population. The etiology and magnitude of insomnia due to changes in circadian rhythms, comorbid conditions, and pharmaceutical agents are not well documented, and the utilization of over-the-counter and non-Food and Drug Administration (FDA)-approved agents to induce sleep (including antihistamines and ethyl alcohol) have not been studied in a natural setting. Evaluating the actual type of insomnia remains much more art than science for the majority of patients and providers. Another issue to consider in this population involves the relationship between patient and physician and the traditional passive patient role. Nonpharmacologic approaches (ie, cognitive behavioral therapy) for insomnia management are effective and usually are first-line therapy. However, the challenges to implementing these approaches may limit their use, thus necessitating pharmacologic therapy. There are currently 3 FDA-approved drug classes for the treatment of insomnia: benzodiazepines, benzodiazepine receptor agonists, and melatonin receptor agonists. Although all agents in these classes are efficacious, benzodiazepines and benzodiazepine receptor agonists are associated with adverse events that must be considered when treating insomnia in the elderly. Melatonin agonists have a mechanism of action that regulates normal sleep-wake cycles and readjusts circadian rhythms, which may confer a better safety profile than traditional sedative-hypnotics that target gamma-aminobutyric acid receptors. Because the 3 currently approved drug classes for insomnia have similar efficacy, safety considerations should be of paramount importance for the elderly patient; however, additional data are needed to appropriately assess the risk-benefit ratios of each.